Compare PRG & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | DVAX |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2004 |
| Metric | PRG | DVAX |
|---|---|---|
| Price | $29.75 | $10.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $35.00 | $26.50 |
| AVG Volume (30 Days) | 477.8K | ★ 1.5M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | $330,514,000.00 |
| Revenue This Year | $1.32 | $24.63 |
| Revenue Next Year | $0.64 | $15.85 |
| P/E Ratio | $7.67 | ★ N/A |
| Revenue Growth | 3.71 | ★ 26.73 |
| 52 Week Low | $23.50 | $9.20 |
| 52 Week High | $48.77 | $14.63 |
| Indicator | PRG | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 48.18 |
| Support Level | $28.88 | $10.76 |
| Resistance Level | $31.52 | $11.00 |
| Average True Range (ATR) | 1.02 | 0.25 |
| MACD | 0.22 | -0.06 |
| Stochastic Oscillator | 56.21 | 20.53 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.